A look into the uptake of semaglutide, what the agent represents, and what is coming further in obesity management.
For many clinicians, the approval of semaglutide for chronic weight management in patients with overweight or obesity may have represented what they had been waiting for in a weight treatment.
Harold Bays, MD, Chief Science Officer, Obesity Medicine Association, explained that while there have been other safe and effacious anti-obesity drugs, there was not a treatment that always met expectations of the patients.
“Up until semaglutide, we just really didn’t have the kind of anti-obesity drug treatment that met the degree of expectation that we often often find from patients where they would like to lose that 10 to 15% of their body weight,” he said. “And I think that’s the biggest central message.”
… read more – watch video
Harold Bays, MD, Chief Science Officer, Obesity Medicine Association
If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.